Structure

InChI Key VCMGMSHEPQENPE-UHFFFAOYSA-N
Smile CNC1(c2ccccc2Cl)CCCCC1=O.Cl
InChI
InChI=1S/C13H16ClNO.ClH/c1-15-13(9-5-4-8-12(13)16)10-6-2-3-7-11(10)14;/h2-3,6-7,15H,4-5,8-9H2,1H3;1H

Physicochemical Descriptors

Property Name Value
Molecular Formula C13H17Cl2NO
Molecular Weight 274.19
AlogP 2.9
Hydrogen Bond Acceptor 2.0
Hydrogen Bond Donor 1.0
Number of Rotational Bond 2.0
Polar Surface Area 29.1
Molecular species NEUTRAL
Aromatic Rings 1.0
Heavy Atoms 16.0

Pharmacology

Action Mechanism of Action Reference
NEGATIVE ALLOSTERIC MODULATOR Glutamate [NMDA] receptor negative allosteric modulator

Metabolites

visNetwork

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Neoplasms 3 D009369 ClinicalTrials
Fractures, Bone 3 D050723 ClinicalTrials
Opioid-Related Disorders 3 D009293 ClinicalTrials
Depressive Disorder, Major 3 D003865 ClinicalTrials
Depressive Disorder, Treatment-Resistant 3 D061218 ClinicalTrials
Wounds and Injuries 3 D014947 ClinicalTrials
Suicidal Ideation 3 D059020 ClinicalTrials
Suicide, Attempted 3 D013406 ClinicalTrials
Psychomotor Agitation 2 D011595 ClinicalTrials
Alcoholism 2 D000437 ClinicalTrials
Cocaine-Related Disorders 2 D019970 ClinicalTrials
Aggression 2 D000374 ClinicalTrials
Pruritus 2 D011537 ClinicalTrials
Tinnitus 2 D014012 ClinicalTrials
Depressive Disorder 2 D003866 ClinicalTrials
Bipolar Disorder 2 D001714 ClinicalTrials
Epilepsy 2 D004827 ClinicalTrials
Subarachnoid Hemorrhage 2 D013345 ClinicalTrials
Bipolar Disorder 2 D001714 ClinicalTrials
Mental Disorders 1 D001523 ClinicalTrials
Persian Gulf Syndrome 1 D018923 ClinicalTrials
Anorexia Nervosa 1 D000856 ClinicalTrials
Stress Disorders, Post-Traumatic 1 D013313 ClinicalTrials
Nasal Polyps 1 D009298 ClinicalTrials

Related Entries

Scaffolds

Parent

Adverse Reactions

System Organ Classification (SOC)
Relative Frequency (%)
Renal and urinary disorders
17.51
Psychiatric disorders
16.38
Injury, poisoning and procedural complications
9.02
Nervous system disorders
8.11
General disorders and administration site conditions
6.89
Cardiac disorders
5.89
Respiratory, thoracic and mediastinal disorders
5.59
Hepatobiliary disorders
4.96
Investigations
4.36
Vascular disorders
4.31
Gastrointestinal disorders
3.13
Infections and infestations
2.77
Metabolism and nutrition disorders
2.19
Immune system disorders
2.08

Cross References

Resources Reference
ChEBI 650657
ChEMBL CHEMBL1714
EPA CompTox DTXSID4040137
FDA SRS O18YUO0I83
Guide to Pharmacology 4233
KEGG C07843
PubChem 60207523
SureChEMBL SCHEMBL26999
ZINC ZINC36294079